SCHEMBL12481336

SCHEMBL12481336

NC(=O)c1ccc([CH]C(F)(F)F)c(F)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.36
▸ XBP1 P17861 2/20 0.36
▸ PDK2 Q15119 3/20 0.36
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ATM Q13315 1/20 0.34
▸ DGAT1 O75907 1/20 0.34
▸ PLA2G1B P04054 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ ATG4B Q9Y4P1 1/20 0.33
▸ CASP1 P29466 1/20 0.32
▸ PBRM1 Q86U86 1/20 0.31
▸ MKNK1 Q9BUB5 1/20 0.31
▸ MKNK2 Q9HBH9 1/20 0.31
▸ MGAM O43451 1/20 0.30
▸ AMY1A P0DUB6 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ SI P14410 1/20 0.30
▸ MGAM2 Q2M2H8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12480251 0.77 KMT2A (0.34) LMNAXBP1PDK2KMT2AMEN1
SCHEMBL16681377 0.75 ALDH1A1 (0.46) LMNAXBP1PDK2PLA2G1BL3MBTL1
SCHEMBL12481481 0.75 KMT2A (0.33) LMNAXBP1KMT2AMEN1ATM
SCHEMBL4513017 0.73 ERN1 (0.32) PBRM1
SCHEMBL378789 0.73 KEAP1 (0.41) DGAT1L3MBTL1
SCHEMBL28074401 0.73 KMT2A (0.50) LMNAPDK2KMT2AMEN1ATM
SCHEMBL2581821 0.73 CES2 (0.48) LMNAXBP1PDK2KMT2AMEN1
SCHEMBL13837016 0.73 KMT2A (0.31) LMNAXBP1KMT2AATMDGAT1
SCHEMBL16649590 0.72 NOTUM (0.33) PDK2KMT2AATMPBRM1MKNK2
SCHEMBL3110380 0.70 ALDH1A1 (0.45) LMNAPDK2L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 — — EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 — — US disclosed
EP-2661433-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) Novartis AG (CH) 2013-11-13 — — EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 — — US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 LMNA 3778/4885XBP1 2448/4885PDK2 4118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback